10-K: Medline Inc. 2025 Annual Report: Growth Amidst Market Shifts

Medline Inc. reports strong net sales growth and strategic acquisitions in its 2025 Annual Report, navigating a dynamic healthcare landscape and post-IPO environment.

Summary

• Net sales increased 11.5% to $28.432 billion for the fiscal year ended December 31, 2025, compared to $25.507 billion in 2024.
• Net income decreased 3.6% to $1.157 billion in 2025, down from $1.200 billion in 2024.
• Adjusted EBITDA increased to $3.467 billion in 2025, up from $3.361 billion in 2024.
• The Medline Brand segment generated $13.720 billion in net sales (48.3% of total) and $3.334 billion in Segment Adjusted EBITDA (80.6% of total) in 2025.
• The Supply Chain Solutions segment generated $14.712 billion in net sales (51.7% of total) and $805 million in Segment Adjusted EBITDA (19.4% of total) in 2025.
• Organic net sales growth was 10.5% in 2025, primarily driven by increased volumes.
• Prime Vendor net sales increased 12.5% to $18.033 billion in 2025, with $1.229 billion from new relationships and $998 million from existing ones.
• Acquisitions contributed $237 million to net sales in 2025.
• The company completed its Initial Public Offering (IPO) on December 18, 2025, generating net proceeds of approximately $7.048 billion.
• IPO proceeds were used to repay $731 million in Euro Term Loans and $3.292 billion in Dollar Term Loans.
• The company repurchased 46,641,142 shares of Class A common stock from certain pre-IPO owners for approximately $1.323 billion in December 2025.
• The net adverse impact to income before taxes from tariffs and tariff developments was approximately $290 million in 2025.
• Anticipates net capital expenditures of approximately $500 million for fiscal year 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting strong revenue growth and strategic positioning, but tempered by a decline in net income and margin pressure from tariffs and new customer onboarding costs.

Positives

• Strong net sales growth of 11.5% to $28.432 billion in 2025, driven by 10.5% organic growth.
• Adjusted EBITDA increased to $3.467 billion in 2025, demonstrating operational strength.
• The Prime Vendor model shows high customer retention (over 98% average over five years) and significant growth, contributing $18.033 billion in net sales in 2025.
• Successful integration of acquisitions (Microtek, Sinclair Dental, United Medco) contributed $237 million in incremental net sales in 2025.
• Operates a differentiated distribution network of 70 global facilities, with 45 in the U.S., providing next-day delivery to 95% of its U.S. customer base.
• Utilizes advanced technology, including AI and robotics, in over 26 million square feet of warehouse space to enhance efficiency and capacity.
• Maintains approximately 25% incremental capacity across its platform to support long-term growth initiatives.
• Possesses a robust intellectual property portfolio with over 2,300 granted patents and more than 450 FDA 510(k) clearances.
• Successfully launched over 250 new products in the last three years, indicating strong innovation capabilities.
• Benefits from diversified global sourcing partnerships with over 600 partners across 40 countries, reducing reliance on any single source.
• A favorable settlement of an intellectual property dispute resulted in a $43 million gain in 2025.
• Net cash provided by operating activities was $1.744 billion in 2025, indicating healthy cash generation from core operations.

Negatives

• Net income decreased by 3.6% to $1.157 billion in 2025, despite significant revenue growth.
• Gross profit as a percentage of sales declined from 27.3% in 2024 to 26.4% in 2025, primarily due to a 115 basis point impact from higher import costs due to tariffs.
• Experienced a net adverse impact to income before taxes of approximately $290 million in 2025 due to tariffs and tariff developments.
• Selling, general, and administrative (SG&A) expenses increased by $416 million (10.1%) in 2025, driven by higher compensation, distribution, and selling/marketing expenses, and acquisition-related costs.
• Other operating expenses increased by $41 million to $78 million in 2025, largely due to higher IPO-related expenses.
• Recorded a foreign exchange loss of $88 million in 2025, a significant negative swing from a $7 million gain in 2024, primarily due to unfavorable Euro exchange rate movements.
• Other expense, net, increased by $21 million (48.8%) to $64 million in 2025, mainly due to higher debt extinguishment and refinancing costs.
• The provision for income taxes increased by $45 million to $91 million in 2025, primarily driven by the global minimum tax under Pillar Two rules.
• Cash used in operating activities for changes in working capital amounted to $783 million in 2025, influenced by increases in trade accounts receivable ($355 million) and inventories ($264 million), and a $166 million payment for a litigation accrual.
• Sales to new Prime Vendor customers typically have lower margins in early periods, which negatively impacted the overall gross profit margin.

Risks

• Global operations are subject to inherent risks including difficulties in staffing and managing foreign operations, sourcing products, establishing distribution channels, labor risks, foreign currency fluctuations, trade agreements, longer payment cycles, difficulties repatriating cash, legal and regulatory compliance (e.g., FCPA), litigation, tariffs, IP protection, unexpected political changes, climate change impacts, and public health emergencies.
• Inability to fully derive anticipated benefits from existing or future acquisitions, joint ventures, investments, dispositions, or other strategic transactions.
• Consolidation in the healthcare industry could lead to more intense competition, loss of existing customers, and increased pressure for price concessions.
• Operating in a highly competitive industry with accelerating pricing pressure and changes in technology, including challenges from online commerce solutions, may require significant adaptation costs.
• Changes to the U.S. and global healthcare environments, including public policy, laws, regulations, and reimbursement levels, may not be favorable and could limit pricing power or product demand.
• Increases in shipping costs or service issues with third-party shippers could harm the business and negatively impact results of operations.
• Significant challenges or delays in sourcing new products and technologies could have an adverse impact on long-term success and market competitiveness.
• Concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations (GPOs) exposes the company to risks of contract expiration or termination.
• Business and operations depend on the proper functioning of critical facilities and distribution networks, which are vulnerable to disruptions from infrastructure malfunction, facility shutdowns, recalls, natural disasters, and public health crises.
• May be required to recognize impairment charges related to goodwill, identified intangible assets, and fixed assets, which would reduce reported assets and earnings.
• Failure to realize expected benefits from new or amended contracts, planned cost savings, and business improvement initiatives could adversely affect financial results.
• Quality problems and product liability claims could lead to recalls, safety alerts, reputational harm, adverse verdicts, or costly settlements.
• Failure to establish and maintain Prime Vendor relationships may cause revenue to decline, and the conversion of Supply Chain Solutions products to Medline Brand products may negatively impact net sales if volume is constant.
• Increased pressure to maintain or decrease the price of goods and services, coupled with an inability to reduce expenses, could materially adversely affect financial condition.
• Any failure by or loss of a third-party manufacturer or supplier, or other manufacturing/supply-related impacts, could result in delays and increased costs.
• Reliance on the proper function, security, and availability of information technology systems and data, as well as those of third parties, exposes the company to cybersecurity threats, data breaches, and related liabilities.
• Subject to extensive and complex laws and governmental regulations (e.g., FDA, DOJ, HHS, EPA, FTC, CPSC, trade regulations, anti-boycott laws, data privacy/security, healthcare fraud/abuse, environmental, operating/security/licensure standards, antitrust/consumer protection), with potential for adverse regulatory actions.
• Use of AI, automated decision-making, and machine learning technologies and the evolving regulatory framework in this area may subject the company to risks or heightened compliance costs.
• Failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject the company to penalties and adversely impact its reputation and financial condition.
• Uncertain global and domestic macro-economic and political conditions, including changes to foreign trade policies, tariffs, geopolitical conflicts (e.g., Ukraine, Middle East), and economic downturns, could materially adversely affect the business.
• Substantial indebtedness could adversely affect financial condition, limit ability to obtain additional financing, divert cash flow for debt payments, and increase vulnerability to economic downturns.
• Credit agreements and indentures impose significant operating and financial restrictions on subsidiaries, potentially limiting business opportunities.
• Medline Inc. is a holding company dependent on distributions from Medline Holdings to pay taxes, make payments under the tax receivable agreement, and pay any dividends.
• The tax receivable agreement confers benefits upon certain pre-IPO owners, and payments may significantly exceed the actual tax benefits realized by Medline Inc.
• The application of certain valuation assumptions under the tax receivable agreement in the case of certain changes of control or other events may impair the ability to consummate change of control transactions or negatively impact the value received by Class A common stock owners.
• Designating Stockholders hold a significant percentage of voting power, and their interests may conflict with those of other stockholders.
• The amended and restated certificate of incorporation does not limit the ability of Sponsors, the Mills family, and certain other pre-IPO investors to compete with the company.
• Will incur increased costs and become subject to additional regulations and requirements as a public company, potentially lowering profits or diverting management's attention.
• Failure to comply with requirements to design, implement, and maintain effective internal controls could have a material adverse effect on the business and stock price.
• The dual-class structure may result in a lower or more volatile market price of Class A common stock or exclusion from certain stock indices.
• The market price of shares of Class A common stock may be volatile or decline regardless of operating performance.
• May be diluted by the future issuance of additional Class A common stock or Common Units in connection with incentive plans, acquisitions, or otherwise.
• May issue preferred stock whose terms could materially adversely affect the voting power or value of Class A common stock.
• If the company or pre-IPO owners sell additional shares of Class A common stock, or are perceived as intending to sell them, the market price could decline.
• Anti-takeover provisions in organizational documents and Delaware law might discourage or delay acquisition attempts.
• Exclusive forum designation limits stockholders' ability to obtain a favorable judicial forum for disputes with the company or its directors, officers, or other employees.

Future Outlook

The company anticipates net capital expenditures for fiscal year 2026 to be approximately $500 million, primarily for the expansion of manufacturing facilities, distribution centers, and further investment in automation. It estimates an incremental net adverse impact to income before taxes from tariffs and tariff developments of approximately $200 million for fiscal year 2026. The company expects continued demand for its broad product portfolio driven by an aging population and the growing prevalence of chronic conditions, and views the ongoing shift of higher acuity procedures to lower-cost sites of care and consolidation of healthcare providers into IDNs as advantageous trends. Medline Brand net sales to non-Prime Vendor customers are expected to continue to grow. There are no current plans to pay dividends on Class A common stock.

Management Comments

• Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes.
• We believe that Medline Brand conversion is mutually beneficial for both our customers and us-the value we provide customers at the outset of a Prime Vendor agreement meaningfully increases over time, as they accrue savings by purchasing our lower cost Medline Brand products, while our profitability grows given the enhanced margin profile of Medline Brand products.
• As our scale grows, we are able to realize further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price.
• We believe that our positive employee relations and total employee experience drive the continual growth of our workforce.
• While the global tariff environment is unpredictable, as a global company with strategically located and owned manufacturing, combined with a broadly diversified sourcing footprint, we believe we are well-positioned to mitigate potential supply chain challenges.
• We believe that our cash and cash equivalents on hand, cash flows from operations, and borrowing availability under our Revolving Credit Facility will fund our ongoing working capital, investing and financing requirements sufficiently for at least the next year and the foreseeable future thereafter.

Industry Context

StockSavvy.ai notes that Medline Inc.'s strong performance in the medical-surgical products and supply chain solutions sector aligns with broader healthcare trends of an aging population and increasing chronic conditions driving demand. The company's Prime Vendor model and integrated manufacturer-distributor approach provide a competitive advantage against traditional distributors like McKesson, Cardinal Health, Owens & Minor, and Henry Schein, who may lack Medline's vertical integration and cost-saving capabilities. The ongoing consolidation in the healthcare industry, including the shift to lower-cost care settings and the formation of IDNs, presents both opportunities and risks, as larger entities gain negotiating power but also seek comprehensive partners like Medline. The increasing regulatory scrutiny on data privacy (HIPAA, GDPR, CCPA) and the emerging framework for AI/Machine Learning technologies are industry-wide challenges that Medline is actively addressing.

Comparison to Industry Standards

• Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care, based on total net sales of med-surg products, differentiating it from competitors who are either manufacturers or distributors but not both at this scale.
• The company's 98% average Prime Vendor retention rate over the past five years indicates strong customer loyalty and service quality, potentially outperforming industry averages for similar long-term distribution agreements.
• Medline's extensive distribution network of 70 global facilities, including 45 in the U.S., providing next-day delivery to 95% of its U.S. customer base, sets a high benchmark for logistics efficiency compared to many competitors.
• The company's investment in AI and robotics technology in over 26 million square feet of warehouse space positions it at the forefront of supply chain optimization within the healthcare industry.
• Medline's intellectual property portfolio with over 2,300 granted patents and 450 FDA 510(k) clearances demonstrates a strong commitment to R&D and product innovation, which is critical in the competitive medical device sector.
• The company's diversified global sourcing network, with no single partner accounting for more than 5% of total spend, provides a level of supply chain resilience that may exceed some industry peers who are more reliant on concentrated supplier bases.

Management Changes

Corporate Governance

Legal Proceedings

• Mass tort litigation in Cook County, Illinois, involving claims by approximately 380 plaintiffs alleging personal injuries associated with the company's ethylene oxide (EtO) activities in Lake County, Illinois.
• A group settlement for the EtO litigation was finalized in March 2025, with a cash payment of $166 million made in the second quarter of 2025, reducing the outstanding liability from $174 million at December 31, 2024.
• Actively pursuing litigation with its excess insurance carriers related to their obligations to reimburse the company for substantially all remaining EtO settlement payments.
• Reached a legal settlement related to an intellectual property dispute with a third party in March 2025, resulting in a recorded gain of $43 million.
• Received a letter in May 2023 from the San Joaquin County District Attorney's Office, in cooperation with other California District Attorneys, notifying of an investigation into alleged violations regarding the company's management and disposal of hazardous, medical, and universal waste at its California facilities, with potential penalties likely to exceed $300,000.

Related Party Transactions

• Long-term debts are held by certain affiliates of the company's private equity sponsors, with terms identical to all other debts issued.
• The company has entered into a Tax Receivable Agreement (TRA) with certain pre-IPO owners, including individuals and entities classified as related parties, which provides for the payment by Medline Inc. to these owners of 90% of certain tax benefits realized or deemed realized by Medline Inc.

Stakeholder Impact

• Shareholders: Potential for dilution from future stock issuances, impact of dual-class structure on voting power and market price, anti-takeover provisions may limit acquisition premiums, TRA payments benefit pre-IPO owners, and market price volatility are key considerations.
• Employees: The company's human capital strategy focuses on attracting, developing, and retaining talent through competitive compensation, benefits, and a safe, inclusive workplace. However, potential unionization attempts and changes in non-compete enforceability could impact employee relations and costs.
• Customers: Benefit from the Prime Vendor model through cost savings, supply chain optimization, and reliable product availability. However, potential price increases due to tariffs or inflation, and the impact of healthcare industry consolidation on purchasing power, are ongoing factors.
• Suppliers: The company relies on a diversified network of third-party manufacturers and suppliers. Supply chain disruptions due to global events or regulatory changes could impact these relationships.
• Creditors: The company's substantial indebtedness and restrictive covenants in debt agreements, along with exposure to interest rate fluctuations, are significant for creditors.

Next Steps

• Continue to enhance product portfolio and tailor service offerings to expand value across the continuum of care.
• Deepen relationships with non-Prime Vendor customers and expand Medline Brand product portfolio to convert them to Prime Vendor agreements.
• Drive customer savings through the conversion of Supply Chain Solutions products to like-for-like Medline Brand products.
• Pursue a disciplined, global mergers and acquisitions strategy focused on adjacent products/services and expansion into new channels/markets.
• Actively monitor developments in the global tariff environment and evaluate potential impacts, implementing mitigation levers such as re-allocating production, leveraging supplier base, optimizing procurement, and selective price increases.
• Anticipate net capital expenditures of approximately $500 million for fiscal year 2026, primarily for expansion of manufacturing facilities, distribution centers, and further investment in automation.
• The independent registered public accounting firm will attest to the effectiveness of internal control over financial reporting in the 2026 Annual Report.

Key Dates

Recommendation

Medline Inc. demonstrates strong operational performance with significant revenue growth and a robust market position, supported by its Prime Vendor model and strategic acquisitions. However, the decline in net income and gross profit margin, coupled with substantial indebtedness and the complexities of its organizational structure and tax receivable agreement, introduce notable financial risks. While the long-term growth drivers in healthcare are favorable, the immediate financial headwinds and the influence of major stockholders suggest a 'hold' position until there is clearer evidence of sustained net income growth and effective mitigation of cost pressures.

Keywords

Medline Inc., Healthcare, Medical-Surgical Products, Supply Chain Solutions, Prime Vendor Model, Annual Report, Financial Performance, IPO, Stock Market, Corporate Governance, Risk Factors, Medical Devices, Distribution Network, Tariffs, Debt, Tax Receivable Agreement, ESG, Cybersecurity, Intellectual Property, Acquisitions